Published in Vaccine Weekly, August 31st, 2005
CytoGenix scientists will prepare the synthetic DNA vaccine designed to stimulate an immune response to a hepatitis B surface antigen. Aldevron will test the activity of this DNA vaccine in models established and validated by Aldevron scientists. Aldevron will conduct the experimental evaluation of the DNA vaccine with the company's proprietary Genetic Immunization and Antibody (GIA) technology.
Dr. Malcolm Skolnick, CytoGenix's president and CEO, commented, "This mutually beneficial...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly